前立腺癌に対するEstracyt(R)の単独投与による治療効果について

Abstract

未治療前立腺癌72例にestracyt 1日4カプセル(estramutine phosphate 560 mg)を単独投与し, 6ヵ月以上経過した51例の臨床効果を検討した.著効34例・有効12例・やや有効4例であった.2年6ヵ月の経過中再燃7例あり, 再燃まで15.8ヵ月であった.PAP・γ-SM:正常値(3～15ヵ月)の後, 18ヵ月以降異常高値を示したのは有転移群であった.副作用は41例にみられ, 乳房肥大33例・心血管系合併症及び脳卒中11例であった

The clinical effect of Estracyt on untreated prostatic carcinoma was evaluated. The subjects consisted of 51 of 71 patients with prostatic carcinoma who were observed for 6 months or more after oral administration of 560 mg of estramustine phosphate. This drug was effective in all patients: markedly effective in 34 (66.6%), moderately effective in 13 (25.5%), and slightly effective in 4 (7.8%). During the observation period varying from 6 months to 2 years and 6 months, 7 patients had recurrence of progression. The interval between the drug administration and recurrence of progression varied from 6 months to 1 year and 10 months (mean, 15.8 months). Prostate acid phosphatase and gamma-seminoprotein remained normal between 3 and 15 months after the administration but became elevated due to recurrence of progression after 18 months or more in some patients. Blood testosterone, luteinizing hormone, and follicle stimulating hormone decreased while blood cortisol increased. Therefore, estrogen was acting effectively. Side effects were observed in 56.9% of the patients, the most frequent being mazoplasia in 33 patients (45.8%), and cardiovascular complications and apoplexy in 11 patients (15.3%). Estracyt was effective for untreated prostatic carcinoma but the problems such as recurrence of progression and side effects require further examination.